#250: Hims & Hers Stock Plummets 35% – Is Now the Time to Buy?
This year has been a wild one for Hims & Hers. Thanks to the shortage of GLP-1 weight loss drugs such as Ozempic, Wegovy, and Zepbound, Hims was able to sell an unapproved compounded semaglutide. This caused sales to soar, with revenue up 95% in its most recent quarter. However, Hims' luck may have run out, as the…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from Stock Club
See all episodes →
Chapters Group: Europe's Mini Constellation Software With Compounding Quality's Pieter Slegers
Ouster & Schaeffler: Two More Investicon Stock Picks, One Year Later | Stock Club 323
Two Overlooked AI Stocks Worth Knowing About
Similar episodes from other shows
More like Stock Club →
A New Name in Weight-Loss Drugs
What’s a hydration break worth & Mr Beat-Up divides Bryce and Ren
JPMorgan’s Sharp Reversal… And The Latest Entry To The Weight Loss Drug Battle 5/20/24
Healthcare is Broken—This Company Wants to Fix It
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.